Cetera Trust Company N.A Takes $360,000 Position in Johnson & Johnson (NYSE:JNJ)

Cetera Trust Company N.A acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,294 shares of the company’s stock, valued at approximately $360,000.

A number of other hedge funds have also modified their holdings of the business. Hussman Strategic Advisors Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $1,646,000. Nikulski Financial Inc. increased its stake in shares of Johnson & Johnson by 3.2% during the 4th quarter. Nikulski Financial Inc. now owns 2,192 shares of the company’s stock worth $343,000 after purchasing an additional 67 shares in the last quarter. Jackson Grant Investment Advisers Inc. increased its stake in shares of Johnson & Johnson by 0.5% during the 4th quarter. Jackson Grant Investment Advisers Inc. now owns 14,306 shares of the company’s stock worth $2,242,000 after purchasing an additional 75 shares in the last quarter. Smith & Howard Wealth Management LLC increased its stake in shares of Johnson & Johnson by 78.6% during the 4th quarter. Smith & Howard Wealth Management LLC now owns 5,985 shares of the company’s stock worth $938,000 after purchasing an additional 2,634 shares in the last quarter. Finally, CWM LLC grew its stake in Johnson & Johnson by 7.4% in the 4th quarter. CWM LLC now owns 356,862 shares of the company’s stock worth $55,935,000 after acquiring an additional 24,515 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total transaction of $9,281,969.19. Following the sale, the executive vice president now owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder & Johnson Johnson sold 3,725 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several analysts have commented on JNJ shares. Bank of America lowered their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Morgan Stanley lowered their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 17th. Raymond James lifted their target price on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Royal Bank of Canada lowered their target price on shares of Johnson & Johnson from $181.00 to $175.00 and set an “outperform” rating for the company in a research note on Wednesday, April 17th. Finally, HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their target price for the stock from $169.00 to $170.00 in a research note on Thursday, April 18th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $175.86.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $146.13 on Friday. The company has a current ratio of 1.16, a quick ratio of 0.91 and a debt-to-equity ratio of 0.38. The firm has a market capitalization of $352.14 billion, a price-to-earnings ratio of 9.11, a PEG ratio of 2.45 and a beta of 0.53. The firm’s fifty day simple moving average is $155.26 and its 200 day simple moving average is $155.32. Johnson & Johnson has a twelve month low of $143.13 and a twelve month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analyst estimates of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.43%. The business’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.68 EPS. As a group, equities research analysts expect that Johnson & Johnson will post 10.65 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Tuesday, May 21st will be given a $1.24 dividend. The ex-dividend date is Monday, May 20th. This represents a $4.96 annualized dividend and a dividend yield of 3.39%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. Johnson & Johnson’s payout ratio is presently 29.68%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.